• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Abcellera Biologics Inc (NQ: ABCL )

    3.850 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,781
    Open 3.850
    Bid (Size) 3.880 (2)
    Ask (Size) 3.950 (48)
    Prev. Close 3.850
    Today's Range 3.850 - 3.850
    52wk Range 3.620 - 8.050
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    3 Stock Gems Hiding in the Nasdaq
    If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks. 
    Via InvestorPlace

    Performance

    YTD
    -32.81%
    -32.81%
    1 Month
    -7.89%
    -7.89%
    3 Month
    -29.49%
    -29.49%
    6 Month
    -3.27%
    -3.27%
    1 Year
    -35.62%
    -35.62%

    More News

    Read More
    5 Of 7 AI Categories Rose, Slightly,Over Past Week
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    AbCellera Reports Q1 2024 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    Recap: AbCellera Biologics Q4 Earnings
    Via Benzinga
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    Via Talk Markets
    AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
    From AbCellera Biologics Inc.
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    Via Talk Markets
    The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
    From AbCellera Biologics Inc.
    Via Business Wire
    AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
    From AbCellera Biologics Inc.
    Via Business Wire
    The 7 Best Penny Stocks to Buy in Q2 2024
    Via InvestorPlace
    AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
    From AbCellera Biologics Inc.
    Via Business Wire
    AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
    From AbCellera Biologics Inc.
    Via Business Wire
    Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
    From AbCellera Biologics Inc.
    Via Business Wire
    AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
    Via Talk Markets
    3 Highly Rated Biotech Stocks to Buy for 300% Gains
    Via InvestorPlace
    AbCellera Announces Resignation of Board Member
    From AbCellera Biologics Inc.
    Via Business Wire
    AbCellera to Present at Upcoming Investor Conferences in March
    From AbCellera Biologics Inc.
    Via Business Wire
    AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    AbCellera Reports Full Year 2023 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    Earnings Scheduled For February 20, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.